Torino Myeloma Conference
April 22, 2004

By IMF Admin on December 22, 2011 7:25 AM | No Comments

Amen Newsletters

By IMF Admin on December 21, 2011 3:10 AM | No Comments

Amen Newsletters

Advocacy Update - December 19, 2011

By IMF Admin on December 19, 2011 6:44 PM | No Comments

Advocacy Update - December 19, 2011

ASH 2011: Dr. Fern

By IMF Admin on December 16, 2011 7:16 AM | No Comments

ASH 2011: Dr. Fern

ASH 2011: Dr. Tacchetti - Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

By IMF Admin on December 10, 2011 5:49 AM | No Comments

ASH 2011: Dr. Tacchetti - Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

ASH 2011: Dr. Rajkumar - An Overview of ASH 2011

By IMF Admin on December 10, 2011 5:49 AM | No Comments

ASH 2011: Dr. Rajkumar - An Overview of ASH 2011

ASH 2011: Murielle Roussel - Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program

By IMF Admin on December 10, 2011 5:49 AM | No Comments

ASH 2011: Murielle Roussel - Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program

ASH 2011: Dr. Zingone - Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

By IMF Admin on December 10, 2011 5:49 AM | No Comments

ASH 2011: Dr. Zingone - Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

ASH 2011: Dr. Sonneveld - Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

By IMF Admin on December 10, 2011 5:48 AM | No Comments

ASH 2011: Dr. Sonneveld - Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

ASH 2011: Dr. Usmani - Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

By IMF Admin on December 10, 2011 5:48 AM | No Comments

ASH 2011: Dr. Usmani - Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

ASH 2011: Dr. Zamagni - Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implic

By IMF Admin on December 10, 2011 5:47 AM | No Comments

ASH 2011: Dr. Zamagni - Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications

ASH 2011: Sr. San Miguel - Continued Overall Survival Benefit After 5 Years? Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Prim

By IMF Admin on December 10, 2011 5:47 AM | No Comments

ASH 2011: Sr. San Miguel - Continued Overall Survival Benefit After 5 Years? Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

ASH 2011: Dr. Usmani - Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

By IMF Admin on December 10, 2011 5:47 AM | No Comments

ASH 2011: Dr. Usmani - Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

ASH 2011: Dr Terragna - A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

By IMF Admin on December 10, 2011 5:47 AM | No Comments

ASH 2011: Dr Terragna - A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

ASH 2011: Dr. San Miguel - Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

By IMF Admin on December 10, 2011 5:46 AM | No Comments

ASH 2011: Dr. San Miguel - Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

ASH 2011: Dr. Zhu - Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

By IMF Admin on December 10, 2011 5:46 AM | No Comments

ASH 2011: Dr. Zhu - Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

ASH 2011: Pellegrino Musto - Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia

By IMF Admin on December 10, 2011 5:46 AM | No Comments

ASH 2011: Pellegrino Musto - Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia

ASH 2011: Dr. Richardson - Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)

By IMF Admin on December 10, 2011 5:45 AM | No Comments

ASH 2011: Dr. Richardson - Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)

ASH 2011: Dr. Vij - Final Results From the Bortezomib-na

By IMF Admin on December 10, 2011 5:45 AM | No Comments

ASH 2011: Dr. Vij - Final Results From the Bortezomib-na

ASH 2011: Dr. Usmani - Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

By IMF Admin on December 10, 2011 5:45 AM | No Comments

ASH 2011: Dr. Usmani - Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

ASH 2011: Dr. San Miguel - Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1

By IMF Admin on December 10, 2011 5:44 AM | No Comments

ASH 2011: Dr. San Miguel - Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1

ASH 2011: Dr. Mark - ClaPD (Clarithromycin/[Biaxin

By IMF Admin on December 10, 2011 5:44 AM | No Comments

ASH 2011: Dr. Mark - ClaPD (Clarithromycin/[Biaxin

ASH 2011: Dr. Niesvizky - Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma

By IMF Admin on December 10, 2011 5:43 AM | No Comments

ASH 2011: Dr. Niesvizky - Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma

ASH 2011: Dr. Siegel - Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

By IMF Admin on December 10, 2011 5:42 AM | No Comments

ASH 2011: Dr. Siegel - Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

ASH 2011: Dr. Mark - T-Bird (thalidomide, clarithromycin/[Biaxin

By IMF Admin on December 10, 2011 5:26 AM | No Comments

ASH 2011: Dr. Mark - T-Bird (thalidomide, clarithromycin/[Biaxin

ASH 2011: Dr. Palumbo - A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ? 65 Years (Yrs) with Newly Diagnosed Multipl

By IMF Admin on December 10, 2011 5:26 AM | No Comments

ASH 2011: Dr. Palumbo - A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ? 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015

ASH 2011: Dr. Moreau - Nouvelles d'ASH 2011

By IMF Admin on December 10, 2011 5:25 AM | No Comments

ASH 2011: Dr. Moreau - Nouvelles d'ASH 2011

ASH 2011: Dr. Paiva - High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

By IMF Admin on December 10, 2011 5:25 AM | No Comments

ASH 2011: Dr. Paiva - High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

ASH 2011: Dr. Niesvizky - Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

By IMF Admin on December 10, 2011 5:25 AM | No Comments

ASH 2011: Dr. Niesvizky - Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with

By IMF Admin on December 10, 2011 5:25 AM | No Comments

ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

ASH 2011: Dr. Palumbo - Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients

By IMF Admin on December 10, 2011 5:24 AM | No Comments

ASH 2011: Dr. Palumbo - Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients

ASH 2011: Dr. Mikhael - Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort

By IMF Admin on December 10, 2011 5:24 AM | No Comments

ASH 2011: Dr. Mikhael - Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort

ASH 2011: Dr. Ludwig - Ein

By IMF Admin on December 10, 2011 5:24 AM | No Comments

ASH 2011: Dr. Ludwig - Ein

ASH 2011: Dr. Ocio - Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

By IMF Admin on December 10, 2011 5:24 AM | No Comments

ASH 2011: Dr. Ocio - Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

ASH 2011: Dr. Palumbo - A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

By IMF Admin on December 10, 2011 5:23 AM | No Comments

ASH 2011: Dr. Palumbo - A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

ASH 2011: Roberto Magalhaes - Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control

By IMF Admin on December 10, 2011 5:23 AM | No Comments

ASH 2011: Roberto Magalhaes - Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control

ASH 2011: Dr. Mateos - Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

By IMF Admin on December 10, 2011 5:23 AM | No Comments

ASH 2011: Dr. Mateos - Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

ASH 2011: Vishal Rana - Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma

By IMF Admin on December 10, 2011 5:22 AM | No Comments

ASH 2011: Vishal Rana - Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma

ASH 2011: Dr. Monaghan - Longitudinal Evaluation of 110 Bone Marrow Aspirates of Multiple Myeloma Patients Treated with Lenalidomide Alone or in Combination with Autologous Stem Cell Transplantation or Alkylators for Early Dysplastic Signs

By IMF Admin on December 10, 2011 5:22 AM | No Comments

ASH 2011: Dr. Monaghan - Longitudinal Evaluation of 110 Bone Marrow Aspirates of Multiple Myeloma Patients Treated with Lenalidomide Alone or in Combination with Autologous Stem Cell Transplantation or Alkylators for Early Dysplastic Signs

ASH 2011: Dr. Palumbo - Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study

By IMF Admin on December 10, 2011 5:22 AM | No Comments

ASH 2011: Dr. Palumbo - Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study

ASH 2011: Dr. Moreau - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Charac

By IMF Admin on December 10, 2011 5:22 AM | No Comments

ASH 2011: Dr. Moreau - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

ASH 2011: Dr. Neben - Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Tr

By IMF Admin on December 10, 2011 5:21 AM | No Comments

ASH 2011: Dr. Neben - Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

ASH 2011: Dr. Palumbo - Una visione d?insieme dell?ASH 2011

By IMF Admin on December 10, 2011 5:21 AM | No Comments

ASH 2011: Dr. Palumbo - Una visione d?insieme dell?ASH 2011

ASH 2011: Dr. Nooka - Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis

By IMF Admin on December 10, 2011 5:21 AM | No Comments

ASH 2011: Dr. Nooka - Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis

ASH 2011: Dr. Richardson - Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

By IMF Admin on December 10, 2011 5:21 AM | No Comments

ASH 2011: Dr. Richardson - Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

ASH 2011: Dr. Popat - An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy

By IMF Admin on December 10, 2011 5:20 AM | No Comments

ASH 2011: Dr. Popat - An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy

ASH 2011: Dr. Richardson - Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Incl

By IMF Admin on December 10, 2011 5:20 AM | No Comments

ASH 2011: Dr. Richardson - Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

ASH 2011: Dr. Mark - A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma

By IMF Admin on December 10, 2011 5:20 AM | No Comments

ASH 2011: Dr. Mark - A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma

ASH 2011: Dr. Richardson - Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study

By IMF Admin on December 10, 2011 5:19 AM | No Comments

ASH 2011: Dr. Richardson - Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study

ASH 2011: Dr. Nooka - The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Co

By IMF Admin on December 10, 2011 5:19 AM | No Comments

ASH 2011: Dr. Nooka - The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

ASH 2011: Dr. Morgan - MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

By IMF Admin on December 10, 2011 5:19 AM | No Comments

ASH 2011: Dr. Morgan - MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

ASH 2011: Dr. Munshi - Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities

By IMF Admin on December 10, 2011 5:19 AM | No Comments

ASH 2011: Dr. Munshi - Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities

ASH 2011: Dr. Ludwig - Serum Heavy/Light Chain and Free Light Chain Measurements Provide Prognostic Information, Allow Creation of a Prognostic Model and Identify Clonal Changes (clonal tiding) Through the Course of Multiple Myeloma (MM).

By IMF Admin on December 10, 2011 5:03 AM | No Comments

ASH 2011: Dr. Ludwig - Serum Heavy/Light Chain and Free Light Chain Measurements Provide Prognostic Information, Allow Creation of a Prognostic Model and Identify Clonal Changes (clonal tiding) Through the Course of Multiple Myeloma (MM).

ASH 2011: Dr. Ludwig - Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physic

By IMF Admin on December 10, 2011 5:02 AM | No Comments

ASH 2011: Dr. Ludwig - Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians

ASH 2011: Dr. L

By IMF Admin on December 10, 2011 5:02 AM | No Comments

ASH 2011: Dr. L

ASH 2011: Dr. Lonial - A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

By IMF Admin on December 9, 2011 9:40 AM | No Comments

ASH 2011: Dr. Lonial - A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

ASH 2011: Dr. Lonial - The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

By IMF Admin on December 9, 2011 9:21 AM | No Comments

ASH 2011: Dr. Lonial - The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

ASH 2011: Dr. Lentzsch - Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study

By IMF Admin on December 9, 2011 9:04 AM | No Comments

ASH 2011: Dr. Lentzsch - Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study

ASH 2011: Dr. Leleu - High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

By IMF Admin on December 9, 2011 8:47 AM | No Comments

ASH 2011: Dr. Leleu - High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

ASH 2011: Dr. Leleu - Final Analysis of MELISSE, a Large Multicentric Observational Study to Determine Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Treated with Immunomodulator Drugs

By IMF Admin on December 9, 2011 8:27 AM | No Comments

ASH 2011: Dr. Leleu - Final Analysis of MELISSE, a Large Multicentric Observational Study to Determine Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Treated with Immunomodulator Drugs

ASH 2011: Dr. Ladetto - Long-Term Results of the GIMEMA VTD Consolidation Trial In Autografted Multiple Myeloma Patients (VEL-03-096): Impact of Minimal Residual Disease Detection by Real Time Quantitative PCR On Late Recurrences and Overall Survival.

By IMF Admin on December 9, 2011 8:07 AM | No Comments

ASH 2011: Dr. Ladetto - Long-Term Results of the GIMEMA VTD Consolidation Trial In Autografted Multiple Myeloma Patients (VEL-03-096): Impact of Minimal Residual Disease Detection by Real Time Quantitative PCR On Late Recurrences and Overall Survival.

ASH 2011: Dr. Lacy - Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years.

By IMF Admin on December 9, 2011 7:48 AM | No Comments

ASH 2011: Dr. Lacy - Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years.

ASH 2011: Dr. Kumar - Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy

By IMF Admin on December 9, 2011 7:31 AM | No Comments

ASH 2011: Dr. Kumar - Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy

ASH 2011: Dr. Kumar - Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia

By IMF Admin on December 9, 2011 7:13 AM | No Comments

ASH 2011: Dr. Kumar - Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia

ASH 2011: Dr. Kumar - Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

By IMF Admin on December 9, 2011 6:56 AM | No Comments

ASH 2011: Dr. Kumar - Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

ASH 2011: Martina Kleber - Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients

By IMF Admin on December 9, 2011 6:36 AM | No Comments

ASH 2011: Martina Kleber - Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients

ASH 2011: Martina Kleber - Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients

By IMF Admin on December 9, 2011 6:19 AM | No Comments

ASH 2011: Martina Kleber - Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients

ASH 2011: Dr. Jakubowiak - Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

By IMF Admin on December 9, 2011 6:02 AM | No Comments

ASH 2011: Dr. Jakubowiak - Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

ASH 2011: Dr. Jagannath - Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study

By IMF Admin on December 9, 2011 5:45 AM | No Comments

ASH 2011: Dr. Jagannath - Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study

ASH 2011: Dr. Jagannath - BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

By IMF Admin on December 9, 2011 5:13 AM | No Comments

ASH 2011: Dr. Jagannath - BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

ASH 2011: Dr. Hillengass - Prognostic Significance of the Number of Focal Lesions in Whole Body Magnetic Resonance Imaging Before and After Autologous Stem Cell Transplantation

By IMF Admin on December 9, 2011 4:59 AM | No Comments

ASH 2011: Dr. Hillengass - Prognostic Significance of the Number of Focal Lesions in Whole Body Magnetic Resonance Imaging Before and After Autologous Stem Cell Transplantation

ASH 2011: Daniel Heintel - High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

By IMF Admin on December 9, 2011 4:58 AM | No Comments

ASH 2011: Daniel Heintel - High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

10 Years after Introduction of the Novel Therapies Survival, Quality of Life, and Treatment Options Significantly Improve

By IMF Admin on December 8, 2011 2:11 PM | No Comments

10 Years after Introduction of the Novel Therapies Survival, Quality of Life, and Treatment Options Significantly Improve

Dr. Durie - An Overview of ASH 2011

By IMF Admin on December 7, 2011 10:50 AM | No Comments

Dr. Durie - An Overview of ASH 2011

Test of UStream

By IMF Admin on December 7, 2011 10:36 AM | 2 Comments

Test of UStream

ASH 2011: Dr. Bruno - Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry

By IMF Admin on December 7, 2011 10:36 AM | No Comments

ASH 2011: Dr. Bruno - Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry

ASH 2011: Dr. Berenson - Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

By IMF Admin on December 7, 2011 10:36 AM | No Comments

ASH 2011: Dr. Berenson - Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

ASH 2011: Dr. Dimopoulos - The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients

By IMF Admin on December 7, 2011 10:35 AM | No Comments

ASH 2011: Dr. Dimopoulos - The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients

ASH 2011: Dr. de Larrea - Impact of Global and Gene-Specific DNA Methylation Pattern in Relapsed Multiple Myeloma Patients Treated with Bortezomib

By IMF Admin on December 7, 2011 10:35 AM | No Comments

ASH 2011: Dr. de Larrea - Impact of Global and Gene-Specific DNA Methylation Pattern in Relapsed Multiple Myeloma Patients Treated with Bortezomib

ASH 2011: Dr. Dai - A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results

By IMF Admin on December 7, 2011 10:35 AM | No Comments

ASH 2011: Dr. Dai - A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results

ASH 2011: Dr. Dimopoulos - Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len+Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)